Top Casino Stocks To Own Right Now

Over the years, I’ve been a big fan of investing in the gaming sector. Long term abnormal returns in sin stocks are well documented, but even in the short term, volatility has often created instances of asymmetric risk/reward opportunities. Over the past several years, and more so than international players like Wynn Resorts (WYNN) or Melco Resorts (MLCO), the regional casino players have truly outperformed. That should not be a surprise given the rest of the market has reacted a similar way: domestic sales good, international sales bad. The United States just has been the place to invest, with regionals seeing strong lift from accelerating consumer confidence and accompanying healthy GDP growth; tax reform and industry consolidation have helped as well. Operationally, margins have seen a lot of lift from cost cutting and less promotional spending.

The past is not the future, and unfortunately Boyd Gaming (BYD) looks to have peaked. Poor market positioning, demographic and population headwinds, and cost pressure from wages all are set to combine to limit EBITDA growth and pressure investor sentiment. With shares near all-time highs, investors would be none the wiser that problems are on the horizon, but I see headwinds. My expectation is for 25-30% downside, with a pair trade against regional peer standout Red Rock Resorts (RRR) set to be a strong generator of potential alpha.

Top Casino Stocks To Own Right Now: Invesco Advantage Municipal Income Trust II(VKI)

Advisors’ Opinion:

  • [By Stephan Byrd]

    Invesco Advantage Municipal Income Tr II (NYSEAMERICAN:VKI) declared a monthly dividend on Tuesday, October 2nd, Wall Street Journal reports. Stockholders of record on Tuesday, October 16th will be given a dividend of 0.0493 per share by the financial services provider on Wednesday, October 31st. This represents a $0.59 annualized dividend and a dividend yield of 5.65%. The ex-dividend date of this dividend is Monday, October 15th.

  • [By Max Byerly]

    Van ECK Associates Corp increased its position in shares of Invesco Advantage Municipal Income Tr II (NYSEAMERICAN:VKI) by 14.9% in the 2nd quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission. The fund owned 138,408 shares of the financial services provider’s stock after purchasing an additional 17,899 shares during the period. Van ECK Associates Corp owned 0.31% of Invesco Advantage Municipal Income Tr II worth $1,475,000 at the end of the most recent quarter.

  • [By Stephan Byrd]

    Invesco Advantage Municipal Income Tr II (NYSEAMERICAN:VKI) declared a monthly dividend on Thursday, August 2nd, Wall Street Journal reports. Investors of record on Tuesday, August 14th will be given a dividend of 0.0517 per share by the financial services provider on Friday, August 31st. This represents a $0.62 annualized dividend and a yield of 5.77%. The ex-dividend date is Monday, August 13th.

  • [By Ethan Ryder]

    Wedbush Securities Inc. bought a new stake in Invesco Advantage Municipal Income Trust II (NYSEAMERICAN:VKI) during the first quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The fund bought 35,963 shares of the financial services provider’s stock, valued at approximately $382,000. Wedbush Securities Inc. owned 0.08% of Invesco Advantage Municipal Income Trust II as of its most recent SEC filing.

Top Casino Stocks To Own Right Now: TransUnion(TRU)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Here are some of the news headlines that may have effected Accern Sentiment’s rankings:

    Get TransUnion alerts:

    MIB and TransUnion Work Together to Minimize Identity Fraud in Life Insurance and Annuities (finance.yahoo.com) C2 Systems Launches Cloud-based Data Aggregation and Decision Engine (prweb.com) Insider Selling: TransUnion (TRU) EVP Sells 30,000 Shares of Stock (americanbankingnews.com) TransUnion (TRU) Expected to Post Quarterly Sales of $538.48 Million (americanbankingnews.com) TransUnion to Present at William Blair Growth Stock Conference (finance.yahoo.com)

    A number of research firms have commented on TRU. Zacks Investment Research upgraded TransUnion from a “hold” rating to a “buy” rating and set a $75.00 price target on the stock in a research note on Tuesday, April 24th. Robert W. Baird upped their price target on TransUnion from $65.00 to $74.00 and gave the stock an “outperform” rating in a research note on Monday, April 23rd. SunTrust Banks upped their price target on TransUnion from $64.00 to $78.00 and gave the stock a “buy” rating in a research note on Monday, April 23rd. Barclays upped their price objective on TransUnion from $65.00 to $75.00 and gave the stock an “overweight” rating in a research report on Monday, April 23rd. Finally, Wells Fargo & Co set a $65.00 price objective on TransUnion and gave the stock a “hold” rating in a research report on Monday, April 23rd. Two research analysts have rated the stock with a hold rating, twelve have given a buy rating and one has given a strong buy rating to the company. The company presently has an average rating of “Buy” and an average target price of $66.64.

  • [By Max Byerly]

    TransUnion (NYSE:TRU) EVP David M. Neenan sold 30,000 shares of the stock in a transaction dated Tuesday, June 5th. The stock was sold at an average price of $70.42, for a total value of $2,112,600.00. Following the completion of the sale, the executive vice president now owns 123,029 shares of the company’s stock, valued at $8,663,702.18. The sale was disclosed in a filing with the Securities & Exchange Commission, which is available through this link.

  • [By Shane Hupp]

    Get a free copy of the Zacks research report on TransUnion (TRU)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Joseph Griffin]

    Get a free copy of the Zacks research report on TransUnion (TRU)

    For more information about research offerings from Zacks Investment Research, visit Zacks.com

  • [By Stephan Byrd]

    Natixis trimmed its stake in shares of TransUnion (NYSE:TRU) by 22.9% in the second quarter, HoldingsChannel reports. The firm owned 248,242 shares of the business services provider’s stock after selling 73,784 shares during the quarter. Natixis’ holdings in TransUnion were worth $17,784,000 at the end of the most recent reporting period.

Top Casino Stocks To Own Right Now: Abeona Therapeutics Inc.(ABEO)

Advisors’ Opinion:

  • [By Joseph Griffin]

    Abeona Therapeutics Inc (NASDAQ:ABEO) – Research analysts at SunTrust Banks lowered their Q3 2018 EPS estimates for shares of Abeona Therapeutics in a report released on Monday, August 13th. SunTrust Banks analyst E. Nash now anticipates that the biopharmaceutical company will post earnings of ($0.23) per share for the quarter, down from their previous forecast of ($0.18). SunTrust Banks currently has a “Positive” rating and a $23.00 target price on the stock. SunTrust Banks also issued estimates for Abeona Therapeutics’ Q4 2018 earnings at ($0.24) EPS, FY2018 earnings at ($0.89) EPS, FY2019 earnings at ($0.89) EPS, FY2020 earnings at ($0.91) EPS, FY2021 earnings at ($0.80) EPS and FY2022 earnings at ($0.76) EPS.

  • [By Shane Hupp]

    HC Wainwright set a $30.00 target price on Abeona Therapeutics (NASDAQ:ABEO) in a research report report published on Monday. The firm currently has a buy rating on the biopharmaceutical company’s stock.

  • [By Max Byerly]

    Abeona Therapeutics Inc (NASDAQ:ABEO)’s share price dropped 5.5% during trading on Monday after the company announced weaker than expected quarterly earnings. The stock traded as low as $12.85 and last traded at $12.90. Approximately 760,507 shares were traded during mid-day trading, a decline of 22% from the average daily volume of 974,694 shares. The stock had previously closed at $13.65.

Top Casino Stocks To Own Right Now: Imprimis Pharmaceuticals, Inc.(IMMY)

Advisors’ Opinion:

  • [By Lisa Levin] Gainers
    Blink Charging Co. (NASDAQ: BLNK) shares jumped 26.5 percent to $6.9042. Blink Charging reported Q1 net income of $2.2 million, versus a year-ago net loss of $3.1 million.
    Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) shares climbed 17.4 percent to $3.11. Eleven Biotherapeutics posted a Q1 loss of $0.11 per share.
    Flanigan's Enterprises, Inc. (NYSE: BDL) shares jumped 17 percent to $27.97 following Q2 results. Flanigan's Enterprises posted Q2 earnings of $0.75 per share on sales of $29.456 million.
    Borqs Technologies, Inc. (NASDAQ: BRQS) rose 15.8 percent to $8.05 after reporting Q1 results.
    Abaxis, Inc. (NASDAQ: ABAX) jumped 15.3 percent to $82.75. Zoetis Inc. (NYSE: ZTS) announced plans to acquire Abaxis for $83 per share in cash.
    21Vianet Group, Inc. (NASDAQ: VNET) gained 15.1 percent to $6.33.
    Gemphire Therapeutics Inc. (NASDAQ: GEMP) rose 13.8 percent to $6.27.
    Enphase Energy, Inc. (NASDAQ: ENPH) gained 12.8 percent to $5.98. H.C. Wainwright initiated coverage on Enphase Energy with a Buy rating.
    PetIQ Inc (NASDAQ: PETQ) shares surged 12.1 percent to $21.68 after reporting a first-quarter sales beat.
    NF Energy Saving Corporation (NASDAQ: NFEC) climbed 11.6 percent to $2.399.
    Allied Healthcare Products, Inc. (NASDAQ: AHPI) surged 11.4 percent to $3.0643.
    Boot Barn Holdings, Inc. (NYSE: BOOT) gained 11.1 percent to $24.40 after the company reported upbeat results for its fourth quarter and issued strong first-quarter earnings guidance.
    Ascena Retail Group, Inc. (NASDAQ: ASNA) rose 10.9 percent to $3.16.
    Sea Limited (NYSE: SE) gained 10.1 percent to $11.71 after reporting Q1 results.
    GEE Group, Inc. (NYSE: JOB) climbed 7.9 percent to $2.61 following Q2 results.
    The ONE Group Hospitality, Inc. (NASDAQ: STKS) gained 7.6 percent to $2.41 after reporting Q1 results.
    Biolinerx Ltd/S ADR (NASDAQ: BLRX) rose 7.3 percent to $0.8798 after the company was granted a patent approval. The clinical-st
  • [By Lisa Levin] Gainers
    Boot Barn Holdings, Inc. (NYSE: BOOT) rose 15.6 percent to $25.40 in pre-market trading after the company reported upbeat results for its fourth quarter and issued strong first-quarter earnings guidance.
    Abaxis, Inc. (NASDAQ: ABAX) rose 15.3 percent to $82.75 in pre-market trading. Zoetis Inc. (NYSE: ZTS) announced plans to acquire Abaxis for $83 per share in cash.
    Calumet Specialty Products Partners, L.P. (NASDAQ: CLMT) rose 12.6 percent to $8.95 in pre-market trading after reporting Q1 results.
    Micro Focus International plc (NYSE: MFGP) shares rose 8.8 percent to $18.59 in the pre-market trading session after the company issued strong revenue forecast for the first fiscal half of 2018.
    HC2 Holdings, Inc. (NASDAQ: HCHC) rose 5.6 percent to $6.60 in pre-market trading.
    Eleven Biotherapeutics, Inc. (NASDAQ: EBIO) shares rose 5.3 percent to $2.79 in pre-market trading. Eleven Biotherapeutics posted a Q1 loss of $0.11 per share.
    Imprimis Pharmaceuticals Inc (NASDAQ: IMMY) rose 5.2 percent to $2.52 in pre-market trading after reporting a first-quarter sales beat.
    Red Violet, Inc. (NASDAQ: RDVT) rose 4.1 percent to $10.35 in pre-market trading after climbing 75.31 percent on Tuesday.
    Xenon Pharmaceuticals Inc (NASDAQ: XENE) rose 3.8 percent to $6.90 in pre-market trading. The stock rose over 10 percent Tuesday after reporting its Phase 1 clinical update on XEN901 demonstrated a favorable PK profile.
    Sea Limited (NYSE: SE) rose 3.5 percent to $11.01 in pre-market trading after reporting Q1 results.
    Teva Pharmaceutical Industries Limited (NYSE: TEVA) shares rose 3.4 percent to $20.98 in pre-market trading after Buffett's Berkshire more than doubled its stake in Teva.
    China Internet Nationwide Financial Services Inc. (NASDAQ: CIFS) shares rose 3.7 percent to $31.30 in pre-market trading after the company reported results for its fourth quarter.
    PetIQ Inc (NASDAQ: PETQ) shares rose 3.4 percent to $20.00 in pre-market t
  • [By Stephan Byrd]

    Headlines about Imprimis Pharmaceuticals (NASDAQ:IMMY) have been trending positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million blog and news sources in real time. Accern ranks coverage of companies on a scale of negative one to one, with scores nearest to one being the most favorable. Imprimis Pharmaceuticals earned a daily sentiment score of 0.25 on Accern’s scale. Accern also gave media headlines about the specialty pharmaceutical company an impact score of 47.393314841388 out of 100, indicating that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the immediate future.

Top Casino Stocks To Own Right Now: EP Energy Corporation(EPE)

Advisors’ Opinion:

  • [By Shane Hupp]

    Shares of Enterprise GP Holdings L.P. (NYSE:EPE) have earned a consensus recommendation of “Hold” from the thirteen brokerages that are currently covering the firm, Marketbeat reports. Three equities research analysts have rated the stock with a sell rating, nine have given a hold rating and one has issued a buy rating on the company. The average 12-month price target among brokerages that have issued ratings on the stock in the last year is $2.65.

  • [By Lisa Levin]

    On Wednesday, the energy shares rose 2.39 percent. Meanwhile, top gainers in the sector included EP Energy Corporation (NYSE: EPE), up 18 percent, and Penn Virginia Corporation (NASDAQ: PVAC) up 23 percent.

  • [By Lisa Levin]

    Wednesday afternoon, the energy shares rose 2.37 percent. Meanwhile, top gainers in the sector included EP Energy Corporation (NYSE: EPE), up 24 percent, and Penn Virginia Corporation (NASDAQ: PVAC) up 24 percent.

  • [By Shane Hupp]

    Enterprise GP Holdings L.P. common stock (NYSE:EPE)’s share price was down 1.7% during trading on Tuesday following insider selling activity. The stock traded as low as $2.40 and last traded at $2.38. Approximately 28,073 shares were traded during mid-day trading, a decline of 98% from the average daily volume of 1,140,837 shares. The stock had previously closed at $2.42.

Top Casino Stocks To Own Right Now: Virtus Investment Partners Inc.(VRTS)

Advisors’ Opinion:

  • [By Ethan Ryder]

    BW Gestao de Investimentos Ltda. grew its holdings in Virtus Investment Partners Inc (NASDAQ:VRTS) by 12.9% during the first quarter, according to the company in its most recent filing with the Securities and Exchange Commission. The firm owned 9,490 shares of the closed-end fund’s stock after acquiring an additional 1,082 shares during the period. BW Gestao de Investimentos Ltda. owned about 0.13% of Virtus Investment Partners worth $1,175,000 as of its most recent SEC filing.

  • [By Motley Fool Transcribers]

    Virtus Investment Partners Inc  (NASDAQ:VRTS)Q4 2018 Earnings Conference CallFeb. 01, 2019, 10:00 a.m. ET

    Contents:
    Prepared Remarks Questions and Answers Call Participants
    Prepared Remarks:

    Operator

  • [By Joseph Griffin]

    BidaskClub lowered shares of Virtus Investment Partners (NASDAQ:VRTS) from a buy rating to a hold rating in a report released on Tuesday morning.

    A number of other research firms also recently commented on VRTS. Zacks Investment Research upgraded Virtus Investment Partners from a hold rating to a buy rating and set a $147.00 price objective for the company in a report on Thursday, March 15th. Sandler O’Neill restated a hold rating and set a $142.00 price objective on shares of Virtus Investment Partners in a report on Thursday, March 15th. TheStreet downgraded Virtus Investment Partners from a b rating to a c+ rating in a report on Wednesday, February 14th. Morgan Stanley lowered their price target on Virtus Investment Partners from $136.00 to $135.00 and set an equal weight rating for the company in a report on Tuesday, April 10th. Finally, Barclays lowered their price target on Virtus Investment Partners from $140.00 to $130.00 and set an equal weight rating for the company in a report on Monday, April 23rd. Nine research analysts have rated the stock with a hold rating and one has given a buy rating to the company. Virtus Investment Partners presently has an average rating of Hold and an average price target of $138.13.

Leave a Reply

Your email address will not be published. Required fields are marked *